Reported revenue from fda approved car t therapies for 2023:
- Kymriah (Novartis) - $2.4 billion
- Yescarta (Gilead/Kite) - $3.6 billion
- Breyanzi (Bristol-Myers Squibb) - $1.5 billion
- Tecartus (Gilead/Kite) - $300 million
- Abecma (Bristol-Myers Squibb) - $1 billion
- Carvykti (Bristol-Myers Squibb/Johnson & Johnson) - $500 million
Total Estimated Revenue for these therapies in 2023: ~$9.3 billion
Projected Growth:
The CAR-T market is expected to continue growing in the coming years, with new approvals, expanding indications, and more therapies entering the market. By 2030, the CAR-T market could reach $30-40 billion as more cancers and indications are targeted, including solid tumors.
Please note that these revenues are estimates and may vary based on company financial reports and market dynamics.
Reported revenue from fda approved car t therapies for...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $27.17K | 6.793M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 41 | 26897271 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 243933 | 1 |
View Market Depth
| Last trade - 15.14pm 20/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |